

LITERATURA

1. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Arlington (VA): American Psychiatric Association; 2004, 114 p.
2. Anders M a Mohr P: Farmakoterapie. In: Herman E, Praško J, Seifertová D: Konsiliární psychiatrie. Medical Tribune, Praha 2007.
3. Angermeyer MC & Matschinger H: Public attitude towards psychiatric treatment. *Acta Psychiatr Scand* 1996; 94: 324–336.
4. Antony MM a Barlow DH: Specific phobia. In *Handbook of Cognitive and Behavioral Treatments for Psychological Disorders*, Caballo VE (eds). Pergamon, Oxford, UK, 1998: 1–22.
5. Appelgate RJ: Diagnosis and management of ischemic heart disease in the patient scheduled to undergo electroconvulsive therapy. *Convulsive Ther* 1997; 13 (3): 128–144.
6. Arendt J a Broadway J: Light and melatonin as zeitgebers in man. *Chronobiology International* 1987; 4: 273–282.
7. Arriago F & Paivat T: Clinical and EEG sleep changes in primary dystymia and generalized anxiety: a comparison with normal subjects. *Neurobiology* 1990–1991; 24: 109–114.
8. Bareš M a Praško J: Depresivní porucha. In: Seifertová D, Praško J, Höschl C (eds): *Postupy v léčbě psychických poruch*. Amepra, Praha 2004.
9. Bartoš A, Řípková D: Biochemické ukazatele Alzheimerovy nemoci včetně derivátů cholesterolu. *Psychiatrie* 2008; 3: 145–146.
10. Baštecký J: Právní a sociální otázky duševně nemocných. In: Janík A (ed): *Vybrané kapitoly z psychiatrie II*. Knižnice IPVZ, Praha 1984; 142–158.
11. Baštecký J: Vybrané soudně psychiatrické otázky. In: Höschl C, Libiger J, Švestka J: *Psychiatrie*. Tigis, Praha 2002; 826–835.
12. Beauchemin KM a Hays P: Phototherapy is a useful adjunct in the treatment of depressed inpatients. *Acta Psychiatr Scand* 1997; 95: 424–427.
13. Beck AT: *Cognitive therapy and the emotional disorders*. New York, Penguin Books 1989, 356 s.
14. Beck AT, Rush AJ, Shaw BF and Emery G: *Cognitive therapy of depression*. Guilford Press, New York, 1979.
15. Beitman BD, Yue D. *Learning Psychotherapy: A Time-Efficient and Research-Based and Outcome-Measured Training Program*. New York, NY: WW Norton; 1999.
16. Bell CJ, Malizia AL, Nutt DJ: The neurobiology of social phobia. *Eur Arch Psychiatry Clin Neurosci* 1999 (suppl 1); 249: S11–S18.

17. Benjamin, L: Interpersonal diagnosis and treatment of personality disorders. New York: Guilford 1993.
18. Beran J: Základy psychoterapie pro lékaře. Grada Publishing 2000; 75–97.
19. Berne E: Jak si lidé hrají, Svoboda Praha, 1970.
20. Betts T: Pseudoseizures: seizures that are not epilepsy. *Lancet* 1990 ii: 9–10.
21. Birbaumer N, Grodd W, Diedrich O et al. fMRI reveals amygdala activation to human faces in social phobics. *Neuroreport* 1998; 9: 1223–1226.
22. Bouček J: Sociální psychiatrie. In: Raboch J, Zvolský P (eds): *Psychiatrie*. Galén, Praha 2001; 503–507.
23. Brandt CA, Meller J, Keweloh L, Hoschel K, Staedt J, Muntz D, Stoppe G: Increased benzodiazepine receptor density in the prefrontal cortex in patients with panic disorder. *Journal of Neural Transmission*, 1998; 105/10–12: 1325–1333.
24. Bremner JD: 2006, Traumatic stress: effects on the brain: *Dialogues. Clin. Neurosci.*, v. 8, no. 4, p. 445–461.
25. Brown, GW, Harris TO, and Eales MJ: 1993, Etiology of anxiety and depressive disorders in an inner-city population. 2. Comorbidity and adversity: *Psychol. Med.*, v. 23, no. 1, p. 155–165.
26. Buchsbaum MS, Someya T, Teng CY, Abel L, Chin S, Najafi A. PET and MRI of the thalamus in never – medicated patients with schizophrenia. *Am J Psychiatry* 1996; 153:191–199.
27. Carrion VG, Weems CF, and Reiss AL, 2007, Stress predicts brain changes in children: a pilot longitudinal study on youth stress, posttraumatic stress disorder, and the hippocampus: *Pediatrics*, v. 119, no. 3, p. 509–516.
28. Carrion VG, Weems CF, and Reiss AL: Stress predicts brain changes in children: a pilot longitudinal study on youth stress, posttraumatic stress disorder, and the hippocampus: *Pediatrics* 2007; 119, no. 3, p. 509–516.
29. Caspi A, et al.: 2003, Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene: *Science*, v. 301, no. 5631, p. 386–389.
30. Caspi A, Moffitt TE, Thornton A, Freedman D, Amell JW, Harrington H, Smeijers J, and Silva PA, 1996, The life history calendar: A research and clinical assessment method for collecting retrospective event-history data: *International Journal of Methods in Psychiatric Research*, v. 6, no. 2, p. 101–114.
31. Charney DS, Nagy LM, Bremner JD, Goddard AW, Yehuda R, Southwick SM: Neurobiological Mechanisms of Human Anxiety. In: Fogel BS, Schiffer RB and Rao SM (ed.): *Neuropsychiatry*. Baltimor, Williams & Wilkins, 1996; 257–286.
32. Chovancova Z, Hlustik P, Kanovsky P: The occurrence of “typical” MRI findings in progressive supranuclear palsy and multiple system atrophy: a retrospective study In: *Journal of Neurology* 2008, Vol 255, suppl 2, p 88.
33. Chromý K: Duševní nemoc. Sociologický a sociálně-psychologický pohled. Avicenum, Praha 1990.
34. Chromý K: Duševní porucha a rodina. In: Janík A (ed): *Vybrané kapitoly z psychiatrie II*. Knižnice IPVZ, Praha 1984; 57–64.
35. Chromý K: Kriminalita. In: Janík A (ed): *Psychiatrie*. Avicenum 1983; 209–212.
36. Chromý K: Modely duševních poruch. In: Janík A (ed): *Vybrané kapitoly z psychiatrie I*. Knižnice IPVZ, Praha 1983; 31–38.
37. Chromý K: Sociální aspekty psychiatrické činnosti. In: Janík A (ed): *Psychiatrie*. Avicenum, Praha 1983; 121–127.

38. Ciompi L: Socialpsychiatrie heute – was ist das? Versuch einer Klärung: Schweiz Arch Neurol Psychiatr 1994; 145: 7–16.
39. Clark DM. Anxiety states: Panic and generalized anxiety. In: Hawton K, Salkovskis PM, Krik J, Clark DM (eds). Cognitive behavioral therapy for psychiatric problems: A practical guide. Oxford: Oxford University Press 1989; 318–344.
40. Clark DM: Anxiety states: Panic and generalized anxiety. In: Hawton K, Salkovskis PM, Krik J and Clark DM (eds): Cognitive behavioral therapy for psychiatric problems: A practical guide. Oxford: Oxford University Press 1989; 318–344.
41. Cloninger CR, Adolfsson R, Svrakic NM: Mapping genes for human personality. *Nat Genet* 1996; 12: 3–4.
42. Cloninger CR. Temperament and personality. *Curr Opin Neurobiol* 1994; 4: 266–73.
43. Congedo M, Lubar JF, Joffe D: Low-resolution electromagnetic tomography neurofeedback. *IEEE Transactions on Neural Systems and Rehabilitation Engineering* 2004; 12: 387–397.
44. Cummings LJ, McRae T, Zhang R: Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. *Am J Geriatr Psychiatry* 2006; 14: 605–612.
45. Davis, M: Are different parts of the extended amygdala involved in fear versus anxiety? *Biological Psychiatry* 1998; 44: 1239–1247.
46. De Cristofaro MTR, Sessarego A, Pupi A, Biondi F, Faravelli C: Brain perfusion abnormalities in drug-naive, lactate-sensitive panic patients, A SPECT study. *Biological Psychiatry* 1993; 33: 505–512.
47. DeBellis MD, Casey BJ, Dahl RE, et al.: A pilot study of amygdala volumes in pediatric generalized anxiety disorder. *Biol Psychiatry* 2000; 48: 51–57.
48. Drapela VJ: Přehled teorií osobnosti. Portál: Praha 1998.
49. Drtílková I: Návrh koncepce oboru psychiatrie – pedopsychiatrie. Psychiatrická společnost ČLS JEP, 2008.
50. Dušek K: Intenzivní péče v psychiatrii. Avicenum, Praha 1988.
51. Eikelmann B: Sociálna psychiatria. Základné poznatky a prax. Edícia Tetralóg, 9. zväzok. Vydavateľstvo F, Trenčín 1999.
52. Elkin I, Shea TM a Watkins JT: National Institute of Mental Health Treatment of Depression Collaborative Research Program. *Arch Gen Psychiatry* 1989; 46: 971–982.
53. Ellis A: Reason and emotion in psychotherapy. New York, Lyle Stuart 1962.
54. Engel G & Romano J: Delirium, a syndrome of cerebral insufficiency. *J Chron Diseases* 1959; 9: 260–277.
55. Enoch MA, Rohrbaugh JW, Davis EZ: Relationship of genetically transmitted alpha EEG traits to anxiety disorders and alcoholism. *Am J Med Genet* 1995; 60: 400–408.
56. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM: Cerebrospinal Fluid tau/ β -Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults *Arch Neurol*. 2007; 64: 343–349.
57. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 dopamine receptor

- occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. *Arch Gen Psychiatry*. 1992; 49: 538–544.
58. Feinstein RE: Personality Traits and Disorders. In: Blumenfeld M a Strain JJ (eds): *Psychosomatic Medicine*. Lippincott Williams & Wilkins, Philadelphia 2006; 843–865.
 59. Floris P, Koers A, Kalkman J, Bleijenberg G, Hagoort P, Meer J, Toni I: Increase in prefrontal cortical volume following cognitive behavioural therapy in patients with chronic fatigue syndrome. *Brain: a journal of neurology* 2008; 131 (Pt 8): 2172–80.
 60. Fontaine R, Breton G, Dery R, Fontaine S, Elle R: Temporal lobe abnormalities in panic disorder: an MRI study. *Biol. Psychiatry*, 1990; 27: 304–310.
 61. Ford B: Deep brain stimulation for Parkinson's disease, Parkinson's Disease Foundation 2006.
 62. Förstl H a spol.: Volumetrische Hirnveränderungen und quantitatives EEG bei normalen Altern und Alzheimer Demenz. *Der Nervenarzt* 1966; 76: 53–61.
 63. Foulkes SH: *Therapeutic group analysis*. George Allen and Unwin. London 1964.
 64. Frodl T, Meisenzahl EM, Zetzsche T, Born C, Groll C, Jager M: Hippocampal changes in patients with a first episode of major depression. *Am J Psychiat* 2002; 159: 1112–1118.
 65. Fuhrman A a Burlingame G. M: *Handbook of group psychotherapy: an empirical and clinical synthesis*. Wiley, New York 1994.
 66. Geddes J: Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *The Lancet* 2003, 8: 799–804.
 67. Giesen-Bloo J, van Dyck R, Spinhoven P, et al.: Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. *Arch Gen Psychiatry* 2006; 63: 649–658.
 68. Giles DE, Jarrett RB, Rush AJ, a spol.: Prospective assessment of electroencephalographic sleep in remitted major depression. *Psychiatry Research* 1993; 46: 269–284.
 69. Golden RN, Bradley BN, Ekstrom RD, Hamer RM, Jacobsen FM, Suppes T, Wisner KL, Nemeroff CB: The efficacy of light therapy in the treatment of mood disorders: A review and meta-analysis of the evidence. *Am J Psychiatry* 2005; 162: 656–662.
 70. Grant BF, Hasin DS, Stinson FS, et al.: Prevalence, correlates, and disability of personality disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. *J Clin Psychiatry* 2004; 65: 948–958.
 71. Grawe K: *Psychologische Therapie*. Gottingen: Hogrefe 1998.
 72. Gross R, Olfson M, Gammerrhoff M, et al.: Borderline personality disorders in primary care. *Arch Intern Med* 2002; 162(1): 53–60.
 73. Hall RCW, Gardner ER, Stickney SK: Physical illness manifesting as psychiatric disease, II: analysis of a state hospital inpatient population. *Arch Gen Psychiatry* 1980; 37: 989–995.
 74. Hanuš H: Soudní psychiatrie. In: Hanuš H (ed): *Obecná psychiatrie*. Vydavatelství Karolinum. Univerzita Karlova 1997; 164–168.
 75. Hanus K, Zapletalek M: Suicidal activity of patients with affective disorders during the preventive use of lithium. *Čes Psychiatr* 1984; 80: 97–100.

76. Hanzlíček L: Psychiatrická encyklopedie. Výzkumný ústav psychiatrický, Praha 1984.
77. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A: The Vermont Longitudinal Study of Persons with Severe Mental Illness II: Long-Term Outcome of Subjects who Retrospectively Met DSM-III Criteria for Schizophrenia. *Am J Psychiatry* 1987; 144: 727–735.
78. Hari R, Levanen S & Raij T: Timing of human cortical functions during cognition: role of MEG. *Trends Cogn Sci* 2000; 4: 455–462.
79. Harlow FM a Harlow MK: Effects of various mother-infant relationships on rhesus monkey behaviors. In Foss BM (ed): *Determinants of infant behavior* (Vol. 4). London, Methuen 1969.
80. Harris AH: *Já jsem OK, ty jsi OK*. 1. vyd. Praha: Pragma, 1997.
81. Haw C, Hawton K, Houston K, Townsend E: Psychiatric and personality disorders in deliberate self-harm patients. *Br J Psychiatry* 2001; 178: 48–54.
82. Herrmann WM & Winterer G: Über die Elektroenzephalographie in der Psychiatrie-gegenwärtiger Stand und Ausblick. *Der Nervenarzt* 1996; 67: 348–359.
83. Hill D: *Psychiatric disorders of epilepsy*. Medical Press 1952; 229: 473–475.
84. Hoffmann H: Young adult chronic patients: How can the most difficult of them be better treated? A review of the literature. *Nervenarzt* 1993; 64: 62–69.
85. Horáček J: Formulace případu v psychiatrii. In: Seifertová D, Praško J, Horáček J, Hoschl C (eds): *Postupy v léčbě v psychiatrii*. Anepra, Medical Tribune, Praha 2008;
86. Horáček J: Formulace případu v psychiatrii. In: Seifertová D, Praško J, Horáček J, Hoschl C: *Postupy v léčbě psychických poruch*. Anepra 2008;
87. Hrdlička, M: Zamyšlení nad dětskou a dorostovou psychiatrií. *Pediatric pro praxi* 2005; 2.
88. Hrubý T a Maršálek P: Event Related Potentials – the P3 wave. *Acta Neurobiologiae Experimentalis* 2003; 63: 55–63.
89. Hülsmeier H: Erfahrungen mit Wohngemeinschaften für psychisch Kranke. *Psychiatr Prax* 1986; 13: 144–152.
90. Hyhlík F a Nakonečný M: *Malá encyklopedie současné psychologie*. Státní pedagogické nakladatelství Praha 1977.
91. Hynie S: *Psychofarmakologie v praxi*, Galén, 1995, 319 s.
92. Jacobs NG, Kenis F, Peeters C, Derom R, Vlietinck, and OJ van: 2006, Stress-related negative affectivity and genetically altered serotonin transporter function: evidence of synergism in shaping risk of depression: *Arch. Gen. Psychiatry*, v. 63, no. 9, p. 989–996.
93. Janicak PG: *Handbook of Psychopharmacotherapy*. Lippicott Williams & Wilkins. Baltimore 1999.
94. Janík A: *Veřejnost a duševně nemocný*. Avicenum, Praha 1987.
95. Jiráček R a Franková V: Organicky podmíněné psychické poruchy. In: Seifertová D, Praško J, Hoschl C, Horáček J (eds): *Postupy v léčbě psychických poruch*. Anepra, Medical Tribune, Praha 2008.
96. Jiráček R, Praško J, Seifertová D, Franková V: Organicky podmíněné poruchy. In: Herman E, Praško J, Seifertová D (eds): *Konsiliární psychiatrie*. Medical Tribune 2007.

97. Kalina K, et al.: *Mezioborový glosář pojmů z oblasti drog a drogových závislostí*. Praha: Filia Nova, 2001.
98. Kauder V, et al.: *Psychosoziale Arbeitshilfen*. Bonn: Psychiatrie-Verlag 1997.
99. Kennard MA, Bueding E, Wortis SB: Some biochemical and electroencephalographic changes in delirium tremens. *Quarterly J Stu Alcohol* 1945; 6: 4–14.
100. Kessler RC, McGonagle KA, Zhai S, Nelson CB, Hughes M, Eshelman S, Wittchen HU, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. *Arch Gen Psychiatry* 1995; 51: 8–19.
101. Kolařík M: *Interakční psychologický výcvik*. Olomouc. UP 2006.
102. Konarski JZ, McIntyre RS, Kennedy SH, Rafi-Tari S, Soczynska JK, Ketter TA. Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. *Bipolar Disorder* 2008; 10: 1–37.
103. Kopeček M, Bareš M, Brunovský M, Stopková P: EEG kordance jako predikátor antidepresivní odpovědi. *Psychiatrie*, 2007; 2: 78–81.
104. Kopeček M, Bareš M, Horáček J, Škrdlantová L: Repetitivní transkraniální magnetická stimulace (rTMS). In: Seifertová D, Praško J, Hoschl C: *Postupy v léčbě psychických poruch*. Amepra, Medical Tribune, Praha 2004.
105. Kopeček M, Horáček J, Závěšická L, Španiel F, Hájek T, Bělohávek O, Paclt I: Regionální vychytávání glukózy (18FDG-PET) u pacientů s 1. epizodou schizofrenie. *Psychiatrie* 2003; 7: 10–13.
106. Koponen H, Partanen J, Paakkonen A: EEG spectral analysis in delirium. *J Neurol Neurosurg Psychiatry* 1989; 52: 980–985.
107. Kratochvíl S: *Klinická hypnóza*, Grada, Praha 2009.
108. Kratochvíl S: *Základy psychoterapie*. Portál, Praha 1997, 392 s.
109. Kratochvíl S: *Základy psychoterapie*. Praha: Portál 1997.
110. Kratochvíl, S.: *Základy psychoterapie*. 4. vydání. Portál, Praha 2002.
111. Kripke DF, Mullaney DJ, Klauber MR, Risch SC, Gillin JC. Controlled trial of bright light for nonseasonal major depressive disorders. *Biol Psychiatry*. 1992 Jan 15; 31(2): 119–134.
112. Lam RW, Goldner EM, Solyom L a Remick RA a spol.: A controlled study of light therapy for bulimia nervosa. *Am J Psychiatry* 1994; 151: 744–750.
113. LeDoux J: Fear and the brain: where have we been, and where are we going? *Biological psychiatry* 1998; 44: 1229–1238.
114. LeDoux JE: Nervous System V. Emotion. In: Blum F. (ed.): *Handbook of Physiology*. Washington: American Physiological Society. 1989, s. 419–459.
115. Lepola U, Nouisiainen U, Puranen M, Reikkinen R, Rimón R: EEG and CT findings in patients with panic disorder. *Biol Psychiatry* 1990; 28: 721–727.
116. Lesser IM, Poland RE, Holcomb C: Electroencephalographic study of nighttime panic attacks. *J Nerv Ment Dis* 1985; 173: 744–746.
117. Leucht S, Barnes TRE, Kissling W, Engel RR, Correl C, Kane JM: Relapse prevention in schizophrenia with next generation antipsychotics: a systematic review and exploratory meta analysis of randomized, controlled trials. *Am J Psychiat*, 2003; 7: 1209–22.
118. Leuchter AF, Uijtdehaage SHJ, Cook IA, O'Hara R & Mandelkern M: Relationship between brain electrical activity and cortical perfusion in normal subjects. *Psychiatry Research: Neuroimaging Section* 1999; 90: 125–140.

119. Levenson H, Butler SF, Powers TA, Beitman BD: Krátka dynamická a interpersonálna terapia. Trenčín, F nakladateľstvo 2005; 174 s.
120. Lewy AJ, Bauer VK, Cutler NL, Sack RL, Ahmed S, Thomas KH, Blood ML a Jackson JML: Morning versus evening light treatment of patients with winter depression. *Arch Gen Psychiatry* 1998; 55: 890–896.
121. Liberman RP, DeRisi WJ, Mueser KT: Social skills training for psychiatric patients. Pergamon Press, New York, 1989.
122. Lieberman JA et al.: Antipsychotic Drug Effects on Brain Morphology in First-Episode Psychosis. *Arch Gen Psychiatry*. 2005; 62: 361–370.
123. Lieberman JA, Stroups TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N. Engl. J. med.* 2005; 353: 1209–23.
124. Lipsitt DR: Some problems in the teaching of psychosomatic medicine. In: Lipowski ZJ, Lipsitt DR, Whybrow PC (eds): *Psychosomatic Medicine: Current Trends and Clinical Applications*. New York, Oxford University Press 1977; 599–611.
125. Lowman RL & Richardson LM: Pseudoepileptic seizures of psychogenic origin: a review of the literature. *Clinical Psychology Review* 1987; 7: 363–389.
126. Lukasová E: *Logoterapie ve výchově*, Portál, 1997.
127. Mackewn, J: (2004). *Gestalt psychoterapie*, Praha, Portál.
128. Marusič P, Tomášek M, Belšan T, Křížová H: Zobrazovací a funkčně-zobrazovací metody v epileptologii. *Neurol. pro Praxi*, 2002; 2: XX–XX.
129. Mathesiasius RG, Jochheim KA, Barolin GB, Heinz C: *Die ICIDH – Bedeutung und Perspektiven*. Berlin Wiesbaden: Ullstein Mosby 1995.
130. Matoušek M: EEG v psychiatrii. In: Hoschl C, Libiger J, Švestka J (eds): *Psychiatrie*. Tigris, Praha 2002; 276–281.
131. Maurer K, Bents W, Löffler W, Hafner H: Seelische Behinderung. Vorlaufen oder soziale Folge der Schizophrenie? *Gesundheitswesen* 1996; 58: 79–85.
132. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwab JM, Kennedy SH: Deep brain stimulation for treatment-resistant depression. *Neuron* 2005; 45(5): 651–60.
133. McDonald, AJ: Organization of Amygdaloid Projections to Prefrontal Cortex and Associated Striatum in the Rat. *Neuroscience*. 1991; 44: s. 1–14.
134. Mezinárodní klasifikace nemocí. 10. revize. Duševní poruchy a poruchy chování: Diagnostická kritéria pro výzkum. (přeloženo z anglického originálu) Praha, Psychiatrické centrum 1996; Zprávy č. 134, 179 p.
135. Miller WR a Rollnick S: *Motivační rozhovory*. SCAN, Tišnov 2003.
136. Miller, W: Motivational interviewing with problem drinkers. *Behavioural Psychotherapy*, 11, str. 147–172, 1983.
137. Millon, T: *Disorders of personality: DSM-IV and beyond*. New York, Wiley, 1996.
138. Molina V, Reig S, Sanz J, Palomo T, Benito C, Sánchez J, Pascau J, Desco M: Changes in cortical volume with olanzapine in chronic schizophrenia, *Pharmacopsychiatry* 2007 Jul; 40(4): 135–9.
139. Morihisa JM, Rosse RB, Gross CD, Balkoski V, Ingraham CA: Laboratory and other diagnostic tests in psychiatry. In: Hales RE & Yudofsky SC (eds): *Essentials of clinical psychiatry*. American Psychiatric Press Inc., Washington 1999; 119–146.

140. Možný P: Motivační rozhovor. *Psychiatrie* 2007.
141. Mravčík V, Chomynová P, Orlíková B, Pešek R, Škařupová K, Škrdlantová E, Miovská L, Gajdošíková H, Vopravil J: Výroční zpráva o stavu ve věcech drog v České republice v roce 2007. Praha, Úřad vlády České republiky, 2008.
142. Mrňa B: Posudková činnost, soudní psychiatrie. In: Bouček J (ed): *Obecná psychiatrie*. Univerzita Palackého v Olomouci, Olomouc 2001; 171–174.
143. Mueller C, Rufer M, Moergeli H, and Bridler R: 2006, Brain imaging in psychiatry – a study of 435 psychiatric in-patients at a university clinic: *Acta Psychiatr. Scand* 2006; 114: 91–100.
144. Munford E, Schlesinger HJ, Grass CV: The effect of psychological intervention on recovery from surgery and heart attacks: an analysis of the literature. *Am J Public Health* 1982; 72: 141–151.
145. Murdoch D a Barker PH. *The base of behavioral therapy*. Blackwell Sci Publ, Oxford 1991.
146. Musenga A, Saracino MA, Sani G, Raggi MA: Antipsychotic and antiepileptic drugs in bipolar disorder: the importance of therapeutic drug monitoring. *urr Med Chem*. 2009; 16(12): 1463–81.
147. National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antipsychotics drugs for the treatment of schizophrenia. *Technology Appraisal Guidance*, No. 43, ref. No 106, June 2002; 22.
148. Nelson J, Chouinard G: Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. *Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol* 1999; 6: 69–83.
149. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. *CNS Drugs*. 2005; 19 Suppl 1: 1–93.
150. Nordahl TE, Semple WE, Gross M, Mellman TA, Stein MB, Goyer P, King AC, Uhde TW, Cohen RM: Cerebral glucose metabolic differences in patients with panic disorder. *Neuropsychopharmacology* 1990; 3: 261–272.
151. Nordahl TE, Stein MB, Semple WE: Regional cerebral metabolic asymmetries replicated in an independent group of patients with panic disorder, *Biolog Psychiatry* 1998; 44/10: 998–1006.
152. Ontiveros A a Fontaine R: Sodium valproate and clonazepam for treatment-resistant panic disorder. *J Psychiatry Neurosci* 1992; 17: 78–80.
153. Öst LG: Age of onset of different phobias. *J Abnormal Psychol* 1987; 96: 223–229.
154. Páleníček T, Janů L, Duška F: Návykové nemoci. In: Seifertová D, Praško J, Horáček J, Hoschl C: *Postupy v léčbě psychických poruch*. Aमेpra, Medical Tribune, Praha 2008; XX–XX.
155. Parry BL, Mahan AM, Mostofi A, Klauber MR, Lew GS a Gillin JC: Light therapy of late luteal phase dysphoric disorder: an extended study. *Am J Psychiatry* 1993; 150: 1417–1419.
156. Parsons T: *The social system*. III: Glencoe 1951.
157. Partonen T, Lonnquist J: Prevention of winter seasonal affective disorder by bright light treatment. *Psychol Med* 1996; 26: 1075–1080.
158. Pascual-Marqui RD, Lehmann D, Koenig T, Kochi K, Merlo MC, Hell D, Koukkou M: Low resolution brain electromagnetic tomography (LORETA)

- functional imaging in acute, neuroleptic-naive, first-episode, productive schizophrenia. 1: *Psychiatry Res.* 1999; 30: 169–79.
159. Pašková B, Praško J, Horáček J, Záleský R, Kopeček M, Škrdlantová L, Bělohlávek O: Identifikace souvislosti vychytávání ¹⁸FDG PET s mírou symptomatologie u panické poruchy. *Psychiatrie* 2003; 7 (Suppl. 3): 6–9.
160. Pavlovský P: Organizace a koncepce psychiatrické péče. In: Malá E, Pavlovský P (eds): *Psychiatrie. Portál.* Praha 2002; 121–122.
161. Pavlovský P: Právní postavení duševně nemocných. In: Malá E, Pavlovský P (eds): *Psychiatrie. Portál.* Praha 2002; 119–120.
162. Perls F: (1996). *Gestalt terapie doslova.* Olomouc, Votobia.
163. Perls F, Hefferline RF, Goodman P: (2004). *Gestalt terapie.* Praha, Triton.
164. Perry JC a Vaillant GE: Personality disorders. In: Kaplan HI, Sadock BJ, Baltimore MD (eds.): *Comprehensive Textbook of Psychiatry, 5th Edition.* Vol. 2. Baltimore, MD, Williams & Wilkins, 1989: 1352–1387.
165. Petráková K: Organizace psychiatrické péče. In: Hanuš H (ed): *Psychiatrie. Univerzita Karlova, Karolinum, Praha* 1997; 155–158.
166. Pines M a Schlapobersky J: Group methods in adult psychiatry: *Oxford Book of Psychiatry, Oxford University Press, 2000:* s. 1442–1462.
167. Pines M: Group analysis and the corrective emotional experience: is it relevant? *Psychoanalytic Inquiry, 1990:* 10: 389–408.
168. Pinsker H, Rosenthal L, McCullough: Dynamic supportive therapy. In: Crits-Christoph P a Barber JP (eds): *Handbook of Short-Term Dynamic Psychotherapy.* New York, Basic Books 1991; 220–247.
169. Polsterovi E a M: *Integrovaná gestalt terapie.* Boskovice, Albert 2000.
170. Popov P: Programy metadonové a jiné substituce. In: Kalina K et al.: *Drogy a drogové závislosti – mezioborový přístup.* Kapitola 8/11. Praha, NMS/Úřad vlády ČR, 2003.
171. Praško J a Grambal A: Depresivní poruchy. *Medical Tribune, v tisku.*
172. Praško J a Šlepecký M: Kognitivně-behaviorální terapie depresivních poruch: *Manuál pro terapeutu.* Praha, Psychiatrické centrum 1995, Zprávy č. 127, 194 s.
173. Praško J, et al.: *Skupinová kognitivně behaviorální terapie depresí.* Psychiatrické centrum, Praha 1998.
174. Praško J, Bareš M, Horáček J, et al.: *Psychotická porucha a její léčba. Příručka pro nemocné a jejich rodiny.* Praha: Maxdorf, 2001: 90.
175. Praško J, Horáček J, Pašková B: Neurobiological aspects of CBT with anxiety disorders. *Psychiatrie* 2003; 7, 4 (Suppl.): 11–12.
176. Praško J, Horáček J, Záleský R, et al.: The change of regional brain metabolism (¹⁸FDG PET) in panic disorder during the treatment with cognitive behavioral therapy or antidepressants *Neuroendocrinological Letters* 2004.
177. Praško J, Kosová J: *Kognitivně-behaviorální terapie úzkostných stavů a depresí.* Praha: Triton 1998, 234 s.
178. Praško J, Možný P, Šlepecký M: *Kognitivně behaviorální terapie psychických poruch.* Praha, Triton 2007.
179. Praško J, Ondráčková I, Šípek J: *Panická porucha a její léčba: přehled problematiky a manuál kognitivně-behaviorálního přístupu k léčbě.* Psychiatrické centrum Praha 1997, Zprávy č. 146: 116 s.

180. Praško J, Šlepecký M, Kopřivová J, Papalová S, Raszka M: Relaxace a biofeedback. In: Herman E, Praško J, Seifertová D (eds): *Konsiliární psychiatrie*. Medical Tribune, Praha 2007.
181. Praško J, Záleský R, Herman E, Hovorka J, Kopeček M, Pašková B: Panická porucha. In: Seifertová D, Praško J, Hoschl C (eds): *Postupy v léčbě psychických poruch*. Amepra, Praha 2004; 139–162.
182. Praško J, Možný P, Šlepecký M (eds): *Kognitivně behaviorální terapie psychických poruch*. Triton, Praha 2007.
183. Praško J: Bright light therapy. *Neuroendocrine Letters* 2008; 29 (suppl 1): 33–64.
184. Praško J, Goldmann P a Zindr V: Urychlení nástupu účinku tricyklických anti-depresiv při použití tří druhů načasování intenzivního bílého světla. *Čs. psychiatrie*, 1989, 84, 6, 373–383.
185. Prochazka J a DiClementi C: Transtheoretical therapy: Toward a more integrative model of change. *Psychotherapy* 1982; 19: 276–288.
186. Rainwater J: (1993). *Vezměte život do vlastních rukou*. Praha, Grada.
187. Reiman EM, Raichle ME, Robins E, Butler FK, Herscovitch P, Fox P, Perlmutter J: The application of positron emission tomography to the study of panic disorder. *Am J Psychiatry* 1986; 143: 469–477.
188. Reiman EM, Raichle ME, Robins E, Mintum MA, Fusselman MJ, Fox PT, Price JL, Hackman KA: Neuroanatomical Correlates of Lactate-Induced Anxiety Attack. *Arch. Gen. Psychiatry* 1989; 47: 493–500.
189. Reker TH a Eikelman B: Ambulante Arbeitstherapie, Ergebnisse einer multizentrischen, prospektiven Evaluationstudie. *Nervenarzt* 1994; 65: 329–337.
190. Rektor J: Návrh novelizace Koncepce oboru psychiatrie z pohledu ambulantní psychiatrie. *Psychiatrická společnost ČLS JEP*, 2008.
191. Rhode M: Přenosy ve skupinách. *Konfrontace* 1994; 5: 1: str. 21–26.
192. Rieger Z: *Loď skupiny*. Konfrontace, Hradec Králové 1998, 190 s.
193. Robinson DJ: *Disordered Personalities*, 2nd Edition, Rapid Psychler Press, 1999.
194. Rogers CR: *Způsob bytí*. Portál: Praha 1998.
195. Rosenberg KP: Gabapentin for chronic insomnia. *Am J Addict.* 2003 May-Jun; 12(3): 273–274.
196. Ruhrmann S, Kasper S, Hawellek A, Martinez B, Höflich G, Nickelsen T, Möller HJ: Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder, *Psychological Medicine* 1998; 28: 923–933.
197. Samuels J, Eaton W, Bienvenu J, et al.: Prevalence and correlates of personality disorders in a community sample. *Br J Psychiatry* 2002; 180: 536–542.
198. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al.: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. *Science* 2003; 8; 301: 805–9.
199. Schiff ND, et al.: Behavioural improvements with thalamic stimulation after severe traumatic brain injury. *Nature* 2007; 448, 600–603. PMID 17671503.
200. Schlaepfer TE, Lieb K: Deep brain stimulation for treatment of refractory depression. *Lancet*. 2005 Oct 22–28; 366(9495): 1420–1422.
201. Schou M. Has the time come to abandon prophylactic lithium treatment? A review for clinicians. *Pharmacopsychiatry*. 1998 Nov; 31(6): 210–5.

202. Segal SP a Kotir PL: Sheltered care residence: Ten-year personal outcome. *Am J Orthopsychiatr* 1993; 63: 80–91.
203. Seifertová D, Libiger J, Švestka J, Mohr P, Praško J: Schizofrenie. In: Seifertová D, Praško J, Höschl C: *Postupy v léčbě psychických poruch*. Amepra, Medical Tribune, Praha 2004.
204. Seifertová D: Elektrokonvulzivní terapie. In: Seifertová D, Praško J, Höschl C, Horáček J (eds). *Postupy v léčbě psychických poruch*. Amepra, Medical Tribune, Praha 2008.
205. Seligman MEP: *Helplessness: On depression, development and death*. Freeman. San Francisco 1975.
206. Shape M & Wessley S: Chronic fatigue syndrome. In: Gelder MG, López – Ibor JJ, Andreasen A (eds): *New Oxford Textbook of Psychiatry*. Oxford University Press 2000, London 1112–1121.
207. Sheline YI: 3D MRI studies of neuroanatomic changes in unipolar major depression: The role of stress and medical comorbidity. *Biol Psychiatry* 2000; 48: 791–800.
208. Shepherd G, Murray A, Muljen M: Perspectives on schizophrenia: A survey of user, family career and professional views regarding effective care. *J Ment Health* 1992; 4: 403–422.
209. Skála J: Rozvíjení vztahu lékař-pacient. Balint, balintovská skupina. In: Skála J. (ed): *Psychoterapie v medicínské praxi*. Praha, Avicenum 1989, s. 106–119.
210. Smeding H, Speelman J, Koning-Haanstra M, et al: (2006). Neuropsychological effects of bilateral STN stimulation in Parkinson disease: A controlled study. *Neurology* 66 (12): 1830–1836.
211. Šonka K: Hypnotika. *Remedia* 2003; 13: 437–441.
212. Squire LR, Wetzel CD, Slater PC: Memory complaint after electroconvulsive therapy: Assesment with a new self-rating instrument. *Biol. Psychiat* 1979; 14: 791–801.
213. Stahl SM: *Essential Psychopharmacology of antipsychotics and mood stabilizers*. Cambridge University Press, Cambridge 2002, 142 p.
214. Stewart RS, Devous MD, Rush AJ, Lane L, Bonte FJ: Cerebral Blood Flow Changes during Socium Lactate – Induced Panic Attack. *Am. J. Psychiatry*, 1988; 145: s. 442–449.
215. Storr A: *Freud*. 1. vyd. Praha: Argo, 1996.
216. Švestka J, Náhunek K: The result of lithium therapy in acute phases of affective psychoses and some other prognostical factors of lithium prophylaxis. *Activ nerv sup* 1975; 17 (4): 270–271. 2).
217. Švestka J, Votava M: Aripiprazol. *Farmakoterapie* 2005; 3: 239–248.
218. Švestka J: Antipsychotika. In: Höschl C, Libiger J, Švestka J (eds). *Psychiatrie*. Praha: Tigris, 2002; 691–741.
219. Švestka J: *Psychofarmaka v klinické praxi*. 1. vydání. Praha: Grada Publishing, 1995: 249.
220. Švestka J: Therapy and prophylaxis of manic-depressive psychosis with lithium carbonate, with respect to possibility of prediction of the therapeutic result. *Acta Facult Med Univ Brunensis* 1979; 65: 25–102.
221. Test MA a Stain LI: Alternative to mental hospital treatment. III. Social cost. *Arch Gen Psychiatry* 1980; 37: 409–412.

222. The Expert Consensus Guideline Series. Treatment of Bipolar Disorder. *J Clin Psychiatry* 1996; 57 (Suppl 12A).
223. Tichý J: Fantomové pocity u tranzverzálních lézí míšních. *Bolest*. 2004; 2: 79.
224. Tikofsky RS, Goldstein MD, Hellman RS, et al: Quantitation of r CBF (SPECT/IMP) in treated and untreated panic disorders patients: comparison with normal controls. *J Nucl Med* 1990; 31: 880.
225. Tomanová J, Synek O, Rodáková I, Švestka J: Hyperprolaktinémie a antipsychotika druhé generace, *Psychiatrie* 2008, supp. 1.
226. Treiman DM & Delgado-Escueta AV: Violence and epilepsy: a critical review. In: Pedley TA & Meldrum BS (eds.): *Recent advances in epilepsy*, vol. 1. Churchill Livingstone, Edinburgh 1983.
227. Valenta M, et al. Rukověť k metodice kurzu ESF. Olomouc 2006.
228. van Haren NE, Hulshoff Pol HE, Schnack HG, et al.: Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. *Biol Psychiatry*. 2008 Jan 1; 63 (1): 106–13.
229. Veljkovič J, Djurič Z: *Psihodrama i sociodrama*. Beograd 1998.
230. Vojáček K: *Autogenní trénink*. Praha: Avicenum, 1988.
231. Vybíral Z a Roubal J: Úvod. In: Vybíral Z a Roubal J (eds): *Psychoterapie, v tisku*.
232. Vymětal J: *Základy lékařské psychologie*. Praha: Psychoanalytické nakladatelství, 1994.
233. Vymětal J: *Lékařská psychologie*. Praha: Portál 2003; 398 s.
234. Vymětal J: *Rogersovská psychoterapie*. Praha: Český spisovatel 1996.
235. Walsh T, et al.: 2008, Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia: *Science*, v. 320, no. 5875, p. 539–543.
236. Wells A: *Cognitive therapy of anxiety disorders: A practice manual and conceptual guide*. Willey, Chicheser 1997, 314 s.
237. Williams D: Neural factors related to habitual aggression: consideration of the differences between those habitual aggressive and others who have committed crimes of violence. *Brain* 1969; 92: 503–520.
238. Wilson RR: *Don't panic. Taking control of anxiety attacks*. Harper & Row, New York, 1987.
239. Wiltfang J, Lewczuk P, Riederer P, et al.: Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. *The World J Biol Psychiatry* 2005; 6: 69–84.
240. Wing JK: Eine praktische Grundlage für die Soziotherapie bei Schizophrenen. In: Huber G (eds): *Therapie, Rehabilitation und Prävention schizophrener Erkrankungen*. Stuttgart: Schattauer 1976.
241. Winston A, Pinsker L, McCullough L: A review of supportive psychotherapy. *Hosp Community Psychiatry* 1986; 37: 1105–1114.
242. Winston A, Rosenthal RN, Pinsker H: *Úvod do podpornej psychoterapie*. F Nakladatelstvo, Trenčín 2004, 202 s.
243. Woods SW, Koster K, Krystal JK, et al.: Yohimbine alters regional cerebral blood flow in panic disorder (letter). *Lancet*, September 1988; 17: 678.
244. Wu JC, Buchbaum MS, Hershey TG, et al.: PET in generalized anxiety disorder. *Biol. Psychiatry* 1991; 29: 1181–1199.

245. Yalom ID: Teorie a praxe skupinové psychoterapie. Konfrontace, Hradec Králové 1999.
246. Young J: Cognitive therapy for personality disorders: A schema-focused approach. Sarasota FL: Professional Resource Exchange 1994, 201 s.
247. Young JE, Klosko JS, and Weishaar ME: Schema therapy: A practitioner's guide. Guilford Press, New York 2003.
248. Zinker J: Tvůrčí proces v gestalt terapii. Brno, ERA group spol. s. r. o. 2004.
249. Žižka V: Návrh novelizace Koncepce oboru psychiatrie – Následná lůžková péče. Psychiatrická společnost ČLS JEP, 2008.
250. Zubin J a Spring B: Vulnerability – a new view of schizophrenia. J Abn Psychol 1977; 86: 103–126.